/
ALDX
$2.05+$0.22 (+12.02%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$110.4M
60M shares
52-week range
$1.07 – $6.18
19% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-9.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $71.0K | $96.3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$71.0K | −$96.3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $29.8M | $44.4M | $24.7M | $44.9M | $47.3M | $29.5M | $48.2M | $25.7M |
| Operating income | −$39.7M | −$63.1M | −$36.4M | −$56.2M | −$62.7M | −$42.8M | −$60.1M | −$35.3M |
| EBITDA | −$38.7M | −$61.4M | −$34.3M | −$55.8M | −$60.1M | −$35.2M | −$53.7M | −$31.7M |
| Net income | −$38.9M | −$60.8M | −$37.6M | −$57.8M | −$62.0M | −$37.5M | −$55.9M | −$33.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.79 | -2.24 | -1.11 | -1.07 | -1.06 | -0.64 | -0.94 | -0.56 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.33 | $-0.33–$-0.33 | 2 |
| 2027 | $11M | $-0.21 | $-0.21–$-0.21 | 3 |
| 2028 | $42M | $-0.03 | $-0.06–$0.00 | 2 |
| 2029 | $64M | $0.15 | $0.15–$0.15 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.91
Price
$2.05
Implied downside
-56%
Peer comparison
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
www.aldeyra.com- Employees
- 7
- IPO / List date
- May 2, 2014
- HQ
- LEXINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds ALDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 863,187 | $1.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALDX yet.
